Leptospirosis puts Guyana to the test:
This article was originally published in Clinica
Executive Summary
An outbreak of leptospirosis in flood-stricken Guyana has been met with a thorough response on the part of national and international surveillance services. Testing is being performed locally and at regional hospitals, backed up by secondary testing for other potential diseases, such as dengue and malaria. Further confirmatory testing is being performed by the Caribbean Epidemiology Centre (CAREC) in Trinidad. The scale of the concern surrounding the situation is that some 120,000 people are being treated prophylactically. An appeal has been launched for medical equipment and supplies, after most healthcare facilities were either destroyed or badly damaged (see Clinica No 1143, p 10).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.